Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ELMD Stock Summary
Top 10 Correlated ETFs
ELMD
In the News
Electromed: Blowout Quarter, Beneficial 2024 Guidance, And Cheap
Electromed reported an impressive quarter and expects beneficial results for 2024, with a total market opportunity of 4.2 million Bronchiectasis patients. The company's growth strategies, including direct-to-consumer marketing and internationalization efforts, could drive significant net sales growth. Electromed's stock repurchase program and recent price dynamics make it an attractive investment opportunity.
Electromed, Inc. (ELMD) Q2 2024 Earnings Call Transcript
Electromed, Inc. (ELMD) Q2 2024 Earnings Call Transcript
Electromed, Inc. (ELMD) Q1 2024 Earnings Call Transcript
Electromed, Inc. (NYSE:ELMD ) Q1 2024 Results Conference Call November 7, 2023 5:00 PM ET Company Participants Mike Cavanaugh - IR, ICR Westwicke Jim Cunniff - President and CEO Brad Nagel - CFO Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Operator Good day, and welcome to the Electromed First Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note today's event is being recorded.
Electromed: May Reversal Vindicating Long-Term Buy Thesis
Electromed continues to rally off previous lows and crossed above the 50DMA last week. SmartVest numbers are ratcheting higher, CMS waiver decision well priced into the equity level.
Electromed, Inc. (ELMD) Q3 2023 Earnings Call Transcript
Electromed, Inc. (NYSE:ELMD ) Q3 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Mike Cavanaugh - Investor Relations Kathleen Skarvan - President and Chief Executive Officer Brad Nagel - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Operator Welcome to the Electromed Third Quarter Fiscal 2023 Financial Results Conference Call [Operator Instructions]. I will now turn the call over to your host, Mike Cavanaugh, Investor Relations.
Electromed, Inc. Schedules its Third Quarter Fiscal 2023 Financial Results Conference Call for May 9, 2023 at 5:00 p.m. ET
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Schedules its Third Quarter Fiscal 2023 Financial Results Conference Call for May 9, 2023 at 5:00 p.m. ET.
Electromed: Reiterating Buy With Sales Rep Conversions Driving Top-Line Growth
Solid Q2 result with upsides versus consensus at the top and bottom lines. Sales force increase converting to further sales growth with >$950,000 in revenue/rep this quarter.
Electromed, Inc. (ELMD) Q2 2023 Earnings Call Transcript
Electromed, Inc. (NYSE:ELMD ) Q2 2023 Earnings Conference Call February 14, 2023 5:00 PM ET Company Participants Mike Cavanaugh – Investor Relations Kathleen Skarvan – President and Chief Executive Officer Brad Nagel – Chief Financial Officer Conference Call Participants Brooks O'Neil – Lake Street Operator Greetings, and welcome to Electromed's Fiscal Second Quarter Earnings Call. At this time all participants are in a listen-only mode.
Electromed: SmartVest Clearance Adds Alpha Opportunity, Rate Buy
Received 510(K) clearance for its SmartVest system last month. Meaningful alpha opportunity in helping patients with complex respiratory disorders, large addressable market.
Electromed, Inc. (ELMD) Q1 2023 Earnings Call Transcript
Electromed, Inc. (NYSE:ELMD ) Q1 2023 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Mike Cavanaugh - IR Kathleen Skarvan - CEO & President Michelle Wirtz - Interim CFO Conference Call Participants Operator Hello, and welcome to the Electromed Fiscal First Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode.
ELMD Financial details
ELMD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.77 | 3.86 | 4.17 | 4.92 | 5.68 | |
Net income per share | 0.24 | 0.5 | 0.28 | 0.27 | 0.37 | |
Operating cash flow per share | 0.31 | 0.5 | 0.36 | -0.08 | 0.16 | |
Free cash flow per share | 0.14 | 0.38 | 0.31 | -0.26 | -0.05 | |
Cash per share | 0.94 | 1.25 | 1.39 | 0.96 | 0.87 | |
Book value per share | 3.1 | 3.6 | 3.78 | 4.03 | 4.45 | |
Tangible book value per share | 3.03 | 3.53 | 3.71 | 3.96 | 4.38 | |
Share holders equity per share | 3.1 | 3.6 | 3.78 | 4.03 | 4.45 | |
Interest debt per share | -0.01 | 0.01 | 0 | 0 | 0.01 | |
Market cap | 43.91M | 129.33M | 96.71M | 81.66M | 90.65M | |
Enterprise value | 36.15M | 118.93M | 84.91M | 73.55M | 83.44M | |
P/E ratio | 22.3 | 31.08 | 40.95 | 35.43 | 28.63 | |
Price to sales ratio | 1.4 | 3.98 | 2.7 | 1.96 | 1.89 | |
POCF ratio | 16.95 | 30.82 | 31.43 | -119.04 | 68.93 | |
PFCF ratio | 36.55 | 40.17 | 36.79 | -36.94 | -226.05 | |
P/B Ratio | 1.71 | 4.28 | 2.98 | 2.39 | 2.41 | |
PTB ratio | 1.71 | 4.28 | 2.98 | 2.39 | 2.41 | |
EV to sales | 1.15 | 3.66 | 2.37 | 1.77 | 1.74 | |
Enterprise value over EBITDA | 9.66 | 20.31 | 22.64 | 20.43 | 18.06 | |
EV to operating cash flow | 13.96 | 28.34 | 27.6 | -107.22 | 63.45 | |
EV to free cash flow | 30.09 | 36.94 | 32.3 | -33.27 | -208.07 | |
Earnings yield | 0.04 | 0.03 | 0.02 | 0.03 | 0.03 | |
Free cash flow yield | 0.03 | 0.02 | 0.03 | -0.03 | 0 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | -2.07 | -1.78 | -3.15 | -2.25 | -1.56 | |
Current ratio | 6.78 | 9.38 | 6.83 | 4.83 | 4.69 | |
Interest coverage | -31.07 | 0 | 0 | 118.88 | 0 | |
Income quality | 1.32 | 1.01 | 1.3 | -0.3 | 0.42 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.02 | 0.03 | 0.05 | 0.03 | 0.02 | |
Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | |
Capex to operating cash flow | -0.54 | -0.23 | -0.15 | 2.22 | -1.3 | |
Capex to revenue | -0.04 | -0.03 | -0.01 | -0.04 | -0.04 | |
Capex to depreciation | -1.5 | -1.32 | -0.73 | -2.43 | -2.8 | |
Stock based compensation to revenue | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | |
Graham number | 4.07 | 6.33 | 4.85 | 4.97 | 6.12 | |
ROIC | 0.07 | 0.13 | 0.07 | 0.07 | 0.08 | |
Return on tangible assets | 0.07 | 0.13 | 0.06 | 0.06 | 0.07 | |
Graham Net | 1.9 | 2.33 | 2.49 | 2.19 | 2.34 | |
Working capital | 20.92M | 25.04M | 27.07M | 27.39M | 29.73M | |
Tangible asset value | 25.15M | 29.65M | 31.75M | 33.57M | 37.06M | |
Net current asset value | 20.92M | 25.03M | 27.01M | 27.35M | 29.65M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 12.66M | 13.93M | 15.77M | 19.38M | 22.98M | |
Average payables | 698.61K | 571.04K | 620.26K | 973K | 1.32M | |
Average inventory | 2.49M | 2.85M | 2.6M | 2.65M | 3.7M | |
Days sales outstanding | 160.41 | 158.56 | 177.88 | 186.96 | 186.93 | |
Days payables outstanding | 28.73 | 27.89 | 29.59 | 45.05 | 43.37 | |
Days of inventory on hand | 128.43 | 154.85 | 91.3 | 113.53 | 133.41 | |
Receivables turnover | 2.28 | 2.3 | 2.05 | 1.95 | 1.95 | |
Payables turnover | 12.7 | 13.09 | 12.34 | 8.1 | 8.42 | |
Inventory turnover | 2.84 | 2.36 | 4 | 3.21 | 2.74 | |
ROE | 0.08 | 0.14 | 0.07 | 0.07 | 0.08 | |
Capex per share | -0.17 | -0.12 | -0.05 | -0.18 | -0.2 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q2
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.39 | 1.43 | 1.6 | 1.44 | 1.6 | |
Net income per share | 0.12 | 0.13 | 0.12 | 0.02 | 0.2 | |
Operating cash flow per share | 0.16 | 0.08 | 0.12 | -0.03 | 0.41 | |
Free cash flow per share | 0.11 | 0.01 | 0.07 | -0.04 | 0.4 | |
Cash per share | 0.82 | 0.8 | 0.87 | 0.82 | 1.22 | |
Book value per share | 4.19 | 4.3 | 4.43 | 4.48 | 4.72 | |
Tangible book value per share | 4.12 | 4.23 | 4.35 | 4.41 | 4.65 | |
Share holders equity per share | 4.19 | 4.3 | 4.43 | 4.48 | 4.72 | |
Interest debt per share | -0.02 | 0 | 0.03 | 0 | 0 | |
Market cap | 88.57M | 88M | 91.16M | 88.7M | 93.23M | |
Enterprise value | 81.66M | 81.22M | 83.95M | 81.68M | 82.79M | |
P/E ratio | 22.66 | 20.47 | 22.06 | 143.07 | 13.92 | |
Price to sales ratio | 7.55 | 7.29 | 6.7 | 7.2 | 6.81 | |
POCF ratio | 64.93 | 136.22 | 91.25 | -363.54 | 26.86 | |
PFCF ratio | 98.08 | 1000 | 163.37 | -235.29 | 27.55 | |
P/B Ratio | 2.51 | 2.42 | 2.42 | 2.32 | 2.31 | |
PTB ratio | 2.51 | 2.42 | 2.42 | 2.32 | 2.31 | |
EV to sales | 6.96 | 6.73 | 6.17 | 6.63 | 6.05 | |
Enterprise value over EBITDA | 64.1 | 62.53 | 49.82 | 229.44 | 33.49 | |
EV to operating cash flow | 59.87 | 125.73 | 84.03 | -334.75 | 23.85 | |
EV to free cash flow | 90.43 | 923 | 150.45 | -216.66 | 24.47 | |
Earnings yield | 0.01 | 0.01 | 0.01 | 0 | 0.02 | |
Free cash flow yield | 0.01 | 0 | 0.01 | 0 | 0.04 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | -5.42 | -5.22 | -4.28 | -19.73 | -4.22 | |
Current ratio | 5.68 | 5.48 | 4.69 | 6.27 | 5.97 | |
Interest coverage | -7.41 | -46 | 7.4 | 0 | 0 | |
Income quality | 1.4 | 0.6 | 0.97 | -1.57 | 2.07 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | |
Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Capex to operating cash flow | -0.34 | -0.86 | -0.44 | 0.55 | -0.03 | |
Capex to revenue | -0.04 | -0.05 | -0.03 | -0.01 | -0.01 | |
Capex to depreciation | -2.79 | -5.42 | -2.31 | -0.62 | -0.42 | |
Stock based compensation to revenue | 0.02 | 0.02 | 0.01 | 0.03 | 0.03 | |
Graham number | 3.3 | 3.51 | 3.48 | 1.35 | 4.56 | |
ROIC | 0.03 | 0.03 | 0.03 | 0 | 0.04 | |
Return on tangible assets | 0.02 | 0.03 | 0.02 | 0 | 0.04 | |
Graham Net | 2.27 | 2.29 | 2.33 | 2.51 | 2.79 | |
Working capital | 28.15M | 28.75M | 29.73M | 30.42M | 32.69M | |
Tangible asset value | 34.77M | 35.79M | 37.06M | 37.61M | 39.73M | |
Net current asset value | 28.12M | 28.72M | 29.65M | 30.35M | 32.64M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 21.8M | 22.6M | 23.88M | 24.31M | 23.78M | |
Average payables | 1.03M | 1.04M | 1.33M | 1.21M | 1.05M | |
Average inventory | 3.57M | 3.46M | 3.84M | 4.35M | 4.62M | |
Days sales outstanding | 169.29 | 172.53 | 162.76 | 175.26 | 154.91 | |
Days payables outstanding | 23.19 | 38.52 | 39.05 | 33.66 | 29.8 | |
Days of inventory on hand | 102.58 | 103.12 | 120.14 | 142.68 | 136.26 | |
Receivables turnover | 0.53 | 0.52 | 0.55 | 0.51 | 0.58 | |
Payables turnover | 3.88 | 2.34 | 2.3 | 2.67 | 3.02 | |
Inventory turnover | 0.88 | 0.87 | 0.75 | 0.63 | 0.66 | |
ROE | 0.03 | 0.03 | 0.03 | 0 | 0.04 | |
Capex per share | -0.05 | -0.07 | -0.05 | -0.02 | -0.01 |
ELMD Frequently Asked Questions
What is Electromed, Inc. stock symbol ?
Electromed, Inc. is a US stock , located in New prague of Mn and trading under the symbol ELMD
What is Electromed, Inc. stock quote today ?
Electromed, Inc. stock price is $16.41 today.
Is Electromed, Inc. stock public?
Yes, Electromed, Inc. is a publicly traded company.